MDT

96.83

-2.02%↓

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

Начало・Списък с акции・Avita Therapeutics Inc

Avita Therapeutics Inc

Затворен

3.87 12.83

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

3.43

Максимум

3.92

Ключови измерители
By Trading Economics
Приходи	-3.3M -13M
Продажби	-1.4M 17M
Марж на печалбата	-77.289
Служители	260
EBITDA	-3.2M -11M

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+30.06% upside

Дивиденти
By Dow Jones
Следващи печалби	12.02.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-15M 106M
Предишно отваряне	-8.96
Предишно затваряне	3.87

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

8.83 / 9.77 Подкрепа & съпротива

Avita Therapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

16.01.2026 г., 23:29 ч. UTC

Горещи акции

Stocks to Watch: Atossa Therapeutics, Union Pacific

16.01.2026 г., 22:48 ч. UTC

Придобивния, сливания и поглъщания

Rail Regulator Sends $71.5 Billion Union Pacific-Norfolk Southern Deal Back for Redo -- 2nd Update

16.01.2026 г., 22:43 ч. UTC

Придобивния, сливания и поглъщания

Union Pacific: Additional Information Requested to Be Provided to Surface Transportation Board

16.01.2026 г., 22:22 ч. UTC

Придобивния, сливания и поглъщания

Rail Regulator Sends $71.5 Billion Union Pacific-Norfolk Southern Deal Back for Redo -- Update

16.01.2026 г., 21:50 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Tech, Media & Telecom Roundup: Market Talk

16.01.2026 г., 21:50 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Auto & Transport Roundup: Market Talk

16.01.2026 г., 21:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

16.01.2026 г., 21:50 ч. UTC

Пазарно говорене

Health Care Roundup: Market Talk

16.01.2026 г., 21:48 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Union Pacific, Norfolk Southern Market Share Ruled as Faulty -- Market Talk

16.01.2026 г., 21:41 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Union Pacific, Norfolk Southern Deal Rejection Leaves Questions -- Market Talk

16.01.2026 г., 21:38 ч. UTC

Придобивния, сливания и поглъщания

Rail Regulator Sends $71.5 Billion Union Pacific-Norfolk Southern Deal Back for Redo -- WSJ

16.01.2026 г., 21:30 ч. UTC

Придобивния, сливания и поглъщания

STB: Union Pacific, Norfolk Southern Application Doesn't Include 'Projected Market Shares' as Required

16.01.2026 г., 21:30 ч. UTC

Придобивния, сливания и поглъщания

STB: Union Pacific, Norfolk Southern Application Doesn't Include Certain Schedules, Documents Expressly Made Part of Merger Agreement

16.01.2026 г., 21:30 ч. UTC

Придобивния, сливания и поглъщания

STB: Union Pacific, Norfolk Southern Application Doesn't Contain Certain Information Required by Regulations

16.01.2026 г., 21:30 ч. UTC

Придобивния, сливания и поглъщания

STB: Application Rejected Without Prejudice to Union Pacific, Norfolk Southern Refiling Revised Application Remedying Deficiencies

16.01.2026 г., 21:30 ч. UTC

Придобивния, сливания и поглъщания

Surface Transportation Board: Union Pacific, Norfolk Southern Major Merger Application Filed Dec. 19 Incomplete

16.01.2026 г., 20:44 ч. UTC

Печалби

5 Takeaways From This Season's Wealth Management Earnings -- Barrons.com

16.01.2026 г., 20:42 ч. UTC

Пазарно говорене

Oil Futures Post Fourth Straight Weekly Gain -- Market Talk

16.01.2026 г., 20:28 ч. UTC

Пазарно говорене

U.S. Natural Gas Slips Ahead of Long Weekend -- Market Talk

16.01.2026 г., 19:12 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Netflix Could Comment on Structure of Warner Bid During 4Q Results -- Market Talk

16.01.2026 г., 18:53 ч. UTC

Пазарно говорене

Global Crude Supply Enough to Absorb Any Iran Disruption -- Market Talk

16.01.2026 г., 18:41 ч. UTC

Пазарно говорене

Netflix's Ad Business Seen as Primary Revenue Driver in 2026 -- Market Talk

16.01.2026 г., 18:31 ч. UTC

Пазарно говорене

U.S. Oil Rig Count Rises By 1 to 410 -- Market Talk

16.01.2026 г., 17:20 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

16.01.2026 г., 17:20 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

16.01.2026 г., 17:20 ч. UTC

Пазарно говорене

Health Care Roundup: Market Talk

16.01.2026 г., 17:03 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

16.01.2026 г., 17:03 ч. UTC

Пазарно говорене

All Eyes on Guidance for European Big Pharma Earnings Season -- Market Talk

16.01.2026 г., 16:32 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Sanofi Needs Dealmaking to Offset Pipeline Disappointments -- Market Talk

16.01.2026 г., 16:20 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

Сравнение с други в отрасъла

Ценова промяна

Avita Therapeutics Inc Прогноза

Ценова цел

By TipRanks

30.06% нагоре

12-месечна прогноза

Среден 4.5 USD 30.06%

Висок 5.5 USD

Нисък 3.5 USD

Според 3 анализатори от Wall Street, предложили 12-месечна ценова цел за Avita Therapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

3 ratings

Купи

Задържане

Продай

Според 3 анализатори, дали борсови рейтинги на Avita Therapeutics Inc през последните 3 месеца.

Техническа оценка

By Trading Central

8.83 / 9.77Подкрепа & съпротива

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Avita Therapeutics Inc

AVITA Medical, Inc., together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions. It develops RECELL GO to control the manual process of disaggregation, filtration, and soak time. The company was formerly known as AVITA Therapeutics, Inc. AVITA Medical, Inc. was incorporated in 2020 and is headquartered in Valencia, California.